All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Pomalidomide is an established immunomodulatory drug for the treatment of multiple myeloma (MM), which directly inhibits myeloma cell growth while enhancing immune activity.1 As part of the MonumenTAL-2 trial, talquetamab is under evaluation for efficacy and safety in the treatment of MM in combination with other agents, including pomalidomide.1
Here, we summarize an oral abstract by Matous et al.1 presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition on the safety and preliminary efficacy results from the talquetamab + pomalidomide arm of the MonumenTAL-2 trial.
TEAE of interest, % |
All patients |
|
---|---|---|
Any grade |
Grade 3/4 |
|
Hematologic |
|
|
Neutropenia |
62.9 |
54.3 |
Anemia |
37.1 |
25.7 |
Thrombocytopenia |
28.6 |
20 |
Non-hematologic |
|
|
Taste related |
85.7 |
N/A |
Skin related |
74.3 |
5.7 |
Nail related |
68.6 |
0 |
CRS |
74.3 |
2.9 |
Infections |
80 |
22.9 |
Pneumonia |
22.9 |
14.3 |
Upper RTI |
22.9 |
2.9 |
COVID-19 |
17.1 |
2.9 |
COVID, coronavirus disease; CRS, cytokine release syndrome; RTI, respiratory tract infection; TEAE, treatment-emergent adverse event. |
Figure 1. Overall response rates in the talquetamab + pomalidomide arm of MonumenTAL-2*
CR, complete response; ORR, overall response rate; Pom, pomalidomide; PR, partial response; QW, every week; Q2W, every two weeks; sCR, stringent complete response; Tal, talquetamab; VGPR, very good partial response.
*Adapted from Matous, et al.1
Key learnings |
---|
|
Subscribe to get the best content related to multiple myeloma delivered to your inbox